A High Throughput Screening Assay System for the Identification of Small Molecule Inhibitors of gsp

Mis-sense mutations in the α-subunit of the G-protein, Gsα, cause fibrous dysplasia of bone/McCune-Albright syndrome. The biochemical outcome of these mutations is constitutively active Gsα and increased levels of cAMP. The aim of this study was to develop an assay system that would allow the identification of small molecule inhibitors specific for the mutant Gsα protein, the so-called gsp oncogene. Commercially available Chinese hamster ovary cells were stably transfected with either wild-type (WT) or mutant Gsα proteins (R201C and R201H). Stable cell lines with equivalent transfected Gsα protein expression that had relatively lower (WT) or higher (R201C and R201H) cAMP levels were generated. These cell lines were used to develop a fluorescence resonance energy transfer (FRET)–based cAMP assay in 1536-well microplate format for high throughput screening of small molecule libraries. A small molecule library of 343,768 compounds was screened to identify modulators of gsp activity. A total of 1,356 compounds with inhibitory activity were initially identified and reconfirmed when tested in concentration dose responses. Six hundred eighty-six molecules were selected for further analysis after removing cytotoxic compounds and those that were active in forskolin-induced WT cells. These molecules were grouped by potency, efficacy, and structural similarities to yield 22 clusters with more than 5 of structurally similar members and 144 singleton molecules. Seven chemotypes of the major clusters were identified for further testing and analyses.

[1]  H. Bourne,et al.  GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours , 1989, Nature.

[2]  H. Bourne,et al.  Rapid GDP release from Gs alpha in patients with gain and loss of endocrine function. , 1994, Nature.

[3]  P. Bianco,et al.  Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsalpha-mutated skeletal progenitor cells. , 1998, The Journal of clinical investigation.

[4]  Paul Herzmark,et al.  Rapid GDP release from Gsα in patients with gain and loss of endocrine function , 1994, Nature.

[5]  M. Collins,et al.  McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia , 2012, Orphanet Journal of Rare Diseases.

[6]  N. Gilula,et al.  Hormonally induced cell shape changes in cultured rat ovarian granulosa cells , 1979, The Journal of cell biology.

[7]  C. Francomano,et al.  Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Eunhee Kim,et al.  Effect of gsp oncogene on somatostatin receptor subtype 1 and 2 mRNA levels in GHRH-responsive GH3 cells , 2005, Pituitary.

[9]  Kevan M. Shokat,et al.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.

[10]  H. Nam,et al.  Activating Mutation of GSα in McCune-Albright Syndrome Causes Skin Pigmentation by Tyrosinase Gene Activation on Affected Melanocytes , 1999, Hormone Research in Paediatrics.

[11]  Roland Seifert,et al.  Inhibitors of membranous adenylyl cyclases. , 2012, Trends in pharmacological sciences.

[12]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[13]  P. Chanson,et al.  McCune-Albright syndrome and acromegaly: clinical studies and responses to treatment in five cases. , 1994, European journal of endocrinology.

[14]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[15]  R. Happle The McCune‐Albright syndrome: a lethal gene surviving by mosaicism , 1986, Clinical genetics.

[16]  A. Maitra,et al.  Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development , 2011, Science Translational Medicine.

[17]  E. Kawasaki,et al.  Two G protein oncogenes in human endocrine tumors. , 1990, Science.

[18]  M. Collins,et al.  McCune-Albright syndrome , 2008, Orphanet journal of rare diseases.

[19]  Adam Yasgar,et al.  Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Ivan,et al.  GH3 cells expressing constitutively active Gsα (Q227L) show enhanced hormone secretion and proliferation , 1997, Molecular and Cellular Endocrinology.

[21]  P. Bianco,et al.  The role of stem cells in fibrous dysplasia of bone and the Mccune-Albright syndrome. , 2007, Pediatric endocrinology reviews : PER.

[22]  Ruili Huang,et al.  A Grid Algorithm for High Throughput Fitting of Dose-Response Curve Data , 2010, Current chemical genomics.

[23]  M. Merino,et al.  Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. , 1991, The New England journal of medicine.

[24]  T. Shawker,et al.  The role of type 1 and type 2 5'-deiodinase in the pathophysiology of the 3,5,3'-triiodothyronine toxicosis of McCune-Albright syndrome. , 2008, The Journal of clinical endocrinology and metabolism.